Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin

Rajapakse Mudiyanselage Gamini Rajapakse; Shashiprabha Punyakantha Dunuweera

doi:doi:10.11648/j.ijcocr.20170203.13

| Peer-Reviewed

Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin

Rajapakse Mudiyanselage Gamini Rajapakse, Shashiprabha Punyakantha Dunuweera

Published in International Journal of Clinical Oncology and Cancer Research (Volume 2, Issue 3)

Received: 8 April 2017 Accepted: 24 April 2017 Published: 22 June 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Cisplatin is the first anticancer drug based on inorganic complexes which was discovered accidentally by Rosenberg in 1965. Cisplatin is now used to treat a wide range of cancers such as head and neck testicular, small-cell lung and non-small-cell lung, bladder, cervical and ovarian cancers. Cisplatin has become the premier in combination therapy for solid tumours such as gastric, bladder, cervical, ovarian, lung, breast, head and neck cancers and some malignant mesothelioma and some less common cancers. This review begins with an introduction to the accidental discovery of cisplatin highlighting the amazing fact of serendipity involved in drug discovery. This will follow a reviewing of chemistry of cisplatin, identification of cis and trans isomers of diamminedicholoroplatinum(II). As for the most relevance to Pharmacy the action of cisplatin is reviewed next. Highlighted there are the reasons for cisplatin toxicity and hence ways and means of reducing cytotoxicity of cisplatin to healthy cells. Finally, the work on encapsulation of cisplatin in porous calcium carbonate nanoparticles for safe and targeted delivery to cancerous cells for more effective and selective action on cancer cells will be discussed.

Published in	International Journal of Clinical Oncology and Cancer Research (Volume 2, Issue 3)
DOI	10.11648/j.ijcocr.20170203.13
Page(s)	65-74
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Anticancer Drug, Discovery of Cisplatin, Chemistry of Cisplatin, Action of Cisplatin, Ways of Reducing Cytotoxicity, Encapsulation, Targeted-Delivery, Slow-Release

References

[1]	Emily Hargrave-Thomas, Bo Yu, and Jóhannes Reynisson, Serendipity in Anticancer Drug Discovery, World Journal of Clinical Oncology (2012) 3(1): 1–6.
[2]	C. Monneret, Platinum Anticancer Drugs. From Serendipity to Rational Design, Annales Pharmaceutiques Françaises (2011) 69(6), 286-95. doi: 10.1016/j.pharma.2011.10.001.
[3]	Ricki Lewis, News From Basic Research to Cancer Drug: The Story of Cisplatin, The Scientist (1999) 13[14] 11.
[4]	Peter G. Rose, M. D., Brian N. Bundy, Ph. D., Edwin B. Watkins, M. D., J. Tate Thigpen, M. D., Gunther Deppe, M. D., Mitchell A. Maiman, M. D., Daniel L. Clarke-Pearson, M. D., and Sam Insalaco, M. D., Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer, New England J Medicine, 1999; 340: 1144-1153April 15, 1999DOI: 10.1056/NEJM199904153401502.
[5]	Emily Hargrave-Thomas, Bo Yu and Jóhannes Reynisson, The Effect of Serendipity in Drug Discovery and Development, Chemistry in New Zealand, January (2012), 17-20.
[6]	Sahdeo Prasad, Subash C. Gupta, Bharat B. Aggarwal, Serendipity in Cancer Drug Discovery: Rational or Coincidence? Trends in Pharmacological Sciences (2016) 37(6), 435–450.
[7]	Jolanta Natalia Latosińska and Magdalena Latosińska, Anticancer Drug Discovery — From Serendipity to Rational Design, Pharmacology, Toxicology and Pharmaceutical Science, Drug Discovery, Ed. Hany A. El-Shemy, ISBN 978-953-51-0906-8, Published: January 23, 2013 under CC BY 3.0 license.
[8]	Rachel_Byrne.docx, The role of Serendipity in Biological Scientific Discoveries, http://www.undergraduatelibrary.org/system/files/3242.pdf, Mini Review.
[9]	Kahlin Cheung-Ong, Guri Giaever, Corey Nislow, DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology, Chemistry & Biology (2013) 20(5), 23 May 2013, 648–659.
[10]	Steinhagen, Henning. "The Evolution Of Drug Discovery: From Traditional Medicines to Modern Drugs. By Enrique Raviña.". N.p., 2017. Print.
[11]	Kotz, J. C.; Purcell, K. F. In Chemistry & Chemical Reactivity, 2nd ed.; Saunders College Publishing: Fort Worth, TX, 1991; pp 2–5.
[12]	Alderden, Rebecca A.; Hall, Matthew D.; Hambley, Trevor W. (2006). "The Discovery and Development of Cisplatin". J. Chemical Education, 83 (5): 728. doi: 10.1021/ed083p728.
[13]	Barnett Rosenberg, Loretta Vancamp and Thomas Krigas, Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, Nature (1965) 205, 698–699.
[14]	Barnett Rosenberg, Loretta Vancamp, James E. Trosko and Virginia H. Mansour, Platinum Compounds: A New Class of Potent Antitumour Agents, Nature (1969) 222, 385 - 386 (26 April 1969); doi: 10.1038/222385a0.
[15]	Barnett Rosenberg and Loretta Vancamp, The Successful Regression of Large Solid Sarcoma 180 Tumors by Platinum Compounds, Cancer Research (1970) 30, 1799-1802.
[16]	Lewis, R. From Basic Research to Cancer Drug: The Story of Cisplatin, The Scientist (1999) 13 (14), 11–14.
[17]	Rosenberg, B. In Nucleic Acid–Metal Ion Interactions; Spiro, T. G., Ed.; Wiley & Sons: New York, 1980; Vol. 1, pp 1–29.
[18]	Kerry L. Cecere, Teaching Old Platinum Compounds New Tricks, Chemical Innovation (2001), 31(3) 51–52.
[19]	Hartmann J. T., Fels L. M., Knop S., Stolt H., Kanz L., Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors, Investigation of New Drugs, 2000; 18: 281–289.
[20]	Hartmann J. T., Lipp H.-P. Toxicity of platinum compounds, Expert Opin. Pharmacother. 2003; 4: 889–901. [PubMed].
[21]	Sastry J., Kellie S. J., Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine, Pediatr. Hematol. Oncol., 2005; 22: 441–445. [PubMed].
[22]	Arany I., Safirstein R. L., Cisplatin nephrotoxicity, Semin. Nephrol., 2003; 23: 460–464.
[23]	Boulikas T. Poly(ADP-ribose) synthesis in blocked and damaged cells and its relation to carcinogen,. Anticancer Res., 1992; 12: 885–898.
[24]	Nasser Hanna and Lawrence H. Einhorn, Journal of Clinical Oncology (2014) 24, 3085-3092.].
[25]	Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, Dou QP, Novel metals and metal complexes as platforms for cancer therapy, Curr Pharm Des., 2010 Jun; 16 (16): 1813-25.
[26]	Wiltshaw, E., Cisplatin in the treatment of cancer, Platinum Metals Review, 1979, 23(3): 90–8.
[27]	Planting A., Catimel G., de Mulder P., de Graeff A., Hoppener F., Verweij J., Oster W., Vermorken J., Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer, Ann. Oncol., 1999; 10: 693–700.
[28]	Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., Saijo N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer, N. Engl. J. Med., 2002; 346: 85–91.
[29]	Gatzemeier U., von Pawel J., ten Velde G., Mattson K., DeMarinis F., Harper P., Salvati F., Robinet G., Lucenti A., Bogarerts J., Gallant G., Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer, J. Clin. Oncol, 2000; 18: 3390–3399.
[30]	Coppin C., Gospodarowicz M., James K., Tannock I., Zee B., Carson J., Peter J., Sullivan D., Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation, J. Clin. Oncol., 1996; 14: 2901–2907.
[31]	Rose P., Bundy B., Watkins E., Thigpen J., Deppe G., Maiman M., Clarke-Pearson D., Insalaco S., Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N. Engl. J. Med., 1999; 340: 1144–1153.
[32]	Bolis G., Favalli G., Danese S., Zanaboni F., Mangili G., Scarabelli C., Tateo S., Valsecchi M., Scarfone G., Richiardi G., Frigerio L., Melpignano M., Villa A., Parazzini F., Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer, J. Clin. Oncol., 1997; 15: 1938–1944.
[33]	Hoskins P., Eisenhauer E., Vergote I., Dubuc-Lissoir J., Fisher B., Grimshaw R., Oza A., Plante M., Stuart G., Vermorken J. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paciltaxel/cisplatin as primary treatment of advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 2000; 18: 4038–4044. [PubMed].
[34]	George B. Kauffman, Michele Peyrone, Discoverer of Cisplatin, Platinum Metals Rev., 2010: 54, 1813–1883250 doi: 10.1595/147106710x534326.
[35]	Andreas R. de Biasi, Jonathan Villena-Vargas and Prasad S. Adusumilli, Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence, Clin Cancer Res. 2014 Nov 1; 20(21): 5384–5391. Published online 2014 Sep 9. doi: 10.1158/1078-0432. CCR-14-1298.
[36]	https://www.nobelprize.org/nobel_prizes/chemistry/laureates/1913/>(accessed: 26/01/2017 @ Peradeniya, Sri Lanka.).
[37]	Kurnakow, N., Ueber complexe Metallbasen; Erste Abhandlung, Journal für Praktische Chemie. 1894; 50: 481–507. doi: 10.1002/prac.18940500144.
[38]	Kauffman, George B., Nikolaĭ Semenovich Kurnakov, The reaction (1893) and the man (1860–1941) a Ninety-year Retrospective View, Polyhedron, 1983, 2(9): 855–863. doi: 10.1016/S0277-5387(00)81400-X.
[39]	Kong, Pi-Chang; Rochon, F. D., Cis- and trans-Platinum Compounds of Substituted Pyrimidines and Their Products from Thiourea in Kurnakov's Reaction, Canadian Journal of Chemistry, 1979, 57 (5): 526–529. doi: 10.1139/v79-086.
[40]	Woollins, J, The Detection of Trace Amounts of trans-Pt(NH3)2Cl2 in the Presence of cis-Pt(NH3)2Cl2, A High Performance Liquid Chromatographic Application of Kurnakow's Test, 1983, 2 (3): 175–178. doi: 10.1016/S0277-5387(00)83954-6.
[41]	Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF, Stability of cisplatin in aqueous solution. Stability of cisplatin in aqueous solution, American Journal of Health-System Pharmacy, 1979; 36 (1) 38-43.
[42]	Book Chapter, Platinum-Based Drugs in Cancer Therapy, Part of the series Cancer Drug Discovery and Development pp 3-35, The Chemistry of Cisplatin in Aqueous Solution, Susan J. Berners-Price and Trevor G. Appleton.
[43]	US patent: Stable aqueous cisplatin solutions, US 4889724 A, Publication date December26, 1986.
[44]	Shaloam Dasari and Paul Bernard Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol., 2014; 0: 364–378. doi: 10.1016/j.ejphar.2014.07.025.
[45]	Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Editors: H Kenneth Walker, MD, W Dallas Hall, MD, and J Willis Hurst, MD., Boston: Butterworths; 1990. ISBN-10: 0-409-90077-X.
[46]	Sooriyaarachchi M, Narendran A, Gailer, J., Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro, Metallomics. 2011; 3 (1): 49-55. doi: 10.1039/c0mt00058b. Epub 2010 Dec 6.
[47]	Bell DN, et al. "Comparative Protein Binding, Stability And Degradation Of Satraplatin, JM118 And Cisplatin In Human Plasma In Vitro. - Pubmed - NCBI". Ncbi.nlm.nih.gov. N.p., 2017. Web. 12 May 2017.
[48]	Giuliano Ciarimboli, Membrane Transporters as Mediators of Cisplatin Effects and Side Effects,, 2012, 2012, Article ID 473829, 18 pages, <http://dx.doi.org/10.6064/2012/473829.>.
[49]	<http://www.ld99.com/reference/old/text/2878909-566.html> Extracellular versus Intracellular Concentration, (accessed 26/01/2017, Peradeniya, Sri Lanka.).
[50]	Johnson N. P., Butour J. L., Villani G., Wimmer F. L., Defais M., Pierson V., Brabec V., Prog. Clin. Biochem. Med., 198; 10, 1-24).
[51]	Lepre C. A., Lippard S. J.. Eckstein F., Lilley D. M. J., Nucleic Acids and Molecular Biology, Berlin, Germany, Springer Verlag, 1990, 4 (pg. 9-38).
[52]	Fichtinger-Schepman A. M. J., Oosterom A. T., Lohman P. H. M., Berends F., Cancer Res., 1987, 47, 3000-3004.
[53]	Pil P., Lippard S. J.. Bertino J. R.., Encyclopedia of Cancer, 1997, vol. I New York, NY Academic Press (pg. 392-410).
[54]	Dijt F. J., Fichtinger-Schepman A. M. J., Berends F., Reedijk J., Cancer Res., 1988; 48, 6058-6062.
[55]	G. Bibiana Onoa Gemma Cervantes Virtudes Moreno M. José Prieto, Study of the interaction of DNA with cisplatin and other Pd(II) and Pt(II) complexes by atomic force microscopy, Nucl Acids Res 1998, 26 (6): 1473-1480. DOI: <https://doi.org/10.1093/nar/26.6.1473.>.
[56]	Jaroslav Malina, Ctirad Hofr, Luciana Maresca, Giovanni Natile and Viktor Brabec, DNA Interactions of Antitumor Cisplatin Analogs Containing Enantiomeric Amine Ligands, Biophysical Journal, 2000, 78(4), 2008–2021. <http://dx.doi.org/10.1016/S0006-3495(00)76748-8.>.
[57]	Ohndorf UM1, Rould MA, He Q, Pabo CO, Lippard SJ, Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins, Nature, 1999 Jun 17; 399 (6737): 708-12.
[58]	Sail Urien & François Lokiec, Population pharmacokinetics of total and unbound plasma cisplatin in adult patients, British Journal of Clinical Pharmacology, 2004, 57: 756–763.
[59]	Vermorken JB, van der Vijgh WJ, Klein I et al., Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin, Clin Pharmacol Ther, 1986: 136–44.
[60]	Bonetti A, Franceschi T, Apostoli P et al., Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors, Ther Drug Monit., 1995: 25–32.
[61]	Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ., Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients, Clin Cancer Res, 1998; 4: 331–6.
[62]	MC, Weiss. "New Cisplatin Analogues In Development. A Review. - Pubmed - NCBI". Ncbi.nlm.nih.gov. N.p., 2017. Web. 12 May 2017.
[63]	Smith I. E. and Talbot D. C., Cisplatin and its analogues in the treatment of advanced breast cancer: A review, British J. of Cancer., 1992; 65(6): 787–793, PMCID: PMC1977765.
[64]	Alessandro Pasini and Franco Zunino, New Cisplatin Analogues-On the Way to Better Antitumor Agents, Angewandte Chemie International Edition, 1987, 26 (7): 615-624.
[65]	<http://chem.libretexts.org/Exemplars_and_Case_Studies/ChemCases/Cisplatin%3A_The_Invention_of_an_Anticancer_Drug/Cisplatin_x13._Further_Studies%2F%2F%2F%2FRecent_Developments > (accessed: 26/01/2017 @ Peradeniya, Sri Lanka.).
[66]	Gabriel Angel Gonzalez Esparza, Synthesis and self-assembly of chemotherapeutic cisplatin analogues, (January 1, 2010). ETD Collection for University of Texas, El Paso. Paper AAI1477786. <http://digitalcommons.utep.edu/dissertations/AAI1477786>.
[67]	Ashish Bhargava, and Ulka N Vaishampayan, Satraplatin: Leading the new generation of oral platinum agents, Expert Opin Investig Drugs., 2009 Nov; 18(11): 10.1517/13543780903362437. doi: 10.1517/13543780903362437.
[68]	Harrap KR, Murrer BA, Giandomenico C, et al., Ammine/amine platinum IV dicarboxylates: A novel class of complexes which circumvent intrinsic cisplatin resistance., In: Howell SB, editor. Platinum and other metal coordination complexes in cancer chemotherapy. Plenum; New York: 1991. pp. 391–9.
[69]	Kelland LR, An update on satraplatin: the first orally available platinum anticancer drug, Expert Opin Investig Drugs., 2000; 9 (6): 1373-82.
[70]	Hamelers IH, van Loenen E, Staffhorst RW, de Kruijff B, de Kroon AI, Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin, Mol Cancer Ther., 2006; 5 (8): 2007-12.
[71]	Chaudhury A, Das S, Bunte RM, Chiu GN, Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft., Int J Nanomedicine, 2012; 7: 739-51.
[72]	Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology, Int J Nanomedicine, 2013; 8: 3309–3319.
[73]	Sadhukha T1, Prabha, Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin, S. AAPS Pharm Sci Tech., 2014; 15(4): 1029-38. doi: 10.1208/s12249-014-0139-2. Epub 2014 May 16.
[74]	VASIR, J, and V LABHASETWAR. "Biodegradable Nanoparticles for Cytosolic Delivery of Therapeutics". N.p., 2017. Print.
[75]	Leamon CP, Low PS, Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis, Proc. Natl. Acad. Sci. U. S. A., 1991; 88 (13): 5572–6. doi: 10.1073/pnas.88.13.5572. PMC 51919. PMID 2062838.
[76]	Leamon CP, Folate-targeted drug strategies for the treatment of cancer, Curr Opin Investig Drugs, 2008, 9 (12): 1277–86. PMID 19037834.
[77]	Low PS, Kularatne SA, Folate-targeted therapeutic and imaging agents for cancer, Curr Opin Chem Biol., 2009; 13 (3): 256–62. doi: 10.1016/j.cbpa.2009.03.022. PMID 19419901.
[78]	Clifford AJ, Arjomand A, Dueker SR, Schneider PD, Buchholz BA, Vogel JS, The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid, Adv. Exp. Med. Biol., 1998; 445: 239–51. doi: 10.1007/978-1-4899-1959-5_15. PMID 9781393.
[79]	Coney LR, Tomassetti A, Carayannopoulos L, et al., Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein, Cancer Res., 1991; 51 (22): 6125–32. PMID 1840502.
[80]	Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M, erexpression of folate binding protein in ovarian cancers, Int. J. Cancer., 1997; 74 (2): 193–8. doi: 10.1002/(SICI)1097-0215 (19970422) 74: 2<193:: AID-IJC10>3.0. CO; 2-F.
[81]	Toffoli G, Russo A, Gallo A, et al., Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer, Int. J. Cancer., 1998; 79 (2): 121–6. doi: 10.1002/(SICI)1097-0215(19980417)79: 2<121:: AID-IJC4>3.0. CO; 2-V. PMID 9583724.
[82]	Hartmann, L. C., Keeney, G. L., Lingle, W. L., Christianson, T. J., Varghese, B., Hillman, D., Oberg, A. L., and Low, P. S., Folate receptor overexpression is associated with poor outcome in breast cancer, International Journal of Cancer, 2007; 121: 938-942.
[83]	Wei, Xia; Andrew Hilgenbrink; Eric Matteson; Michael Lockwood; Ji-Xin Cheng; Philip Low, A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages, Blood, 2008; 113: 438–446. doi: 10.1182/blood-2008-04-150789.
[84]	S. P. Dunuweera and R. M. G. Rajapakse, Synthesis of Unstable Vaterite Polymorph of Hollow Calcium Carbonate Nanoparticles and Encapsulation of the Anticancer Drug Cisplatin, Journal of Advances in Medical and Pharmaceutical Sciences, 10(4): 2016; Article No. JAMPS.29784.

Cite This Article

Plain Text BibTeX RIS

APA Style

Rajapakse Mudiyanselage Gamini Rajapakse, Shashiprabha Punyakantha Dunuweera. (2017). Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin. International Journal of Clinical Oncology and Cancer Research, 2(3), 65-74. https://doi.org/10.11648/j.ijcocr.20170203.13

Copy | Download

ACS Style

Rajapakse Mudiyanselage Gamini Rajapakse; Shashiprabha Punyakantha Dunuweera. Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin. Int. J. Clin. Oncol. Cancer Res. 2017, 2(3), 65-74. doi: 10.11648/j.ijcocr.20170203.13

Copy | Download

AMA Style

Rajapakse Mudiyanselage Gamini Rajapakse, Shashiprabha Punyakantha Dunuweera. Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin. Int J Clin Oncol Cancer Res. 2017;2(3):65-74. doi: 10.11648/j.ijcocr.20170203.13

Copy | Download

@article{10.11648/j.ijcocr.20170203.13,
  author = {Rajapakse Mudiyanselage Gamini Rajapakse and Shashiprabha Punyakantha Dunuweera},
  title = {Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {2},
  number = {3},
  pages = {65-74},
  doi = {10.11648/j.ijcocr.20170203.13},
  url = {https://doi.org/10.11648/j.ijcocr.20170203.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20170203.13},
  abstract = {Cisplatin is the first anticancer drug based on inorganic complexes which was discovered accidentally by Rosenberg in 1965. Cisplatin is now used to treat a wide range of cancers such as head and neck testicular, small-cell lung and non-small-cell lung, bladder, cervical and ovarian cancers. Cisplatin has become the premier in combination therapy for solid tumours such as gastric, bladder, cervical, ovarian, lung, breast, head and neck cancers and some malignant mesothelioma and some less common cancers. This review begins with an introduction to the accidental discovery of cisplatin highlighting the amazing fact of serendipity involved in drug discovery. This will follow a reviewing of chemistry of cisplatin, identification of cis and trans isomers of diamminedicholoroplatinum(II). As for the most relevance to Pharmacy the action of cisplatin is reviewed next. Highlighted there are the reasons for cisplatin toxicity and hence ways and means of reducing cytotoxicity of cisplatin to healthy cells. Finally, the work on encapsulation of cisplatin in porous calcium carbonate nanoparticles for safe and targeted delivery to cancerous cells for more effective and selective action on cancer cells will be discussed.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin
AU  - Rajapakse Mudiyanselage Gamini Rajapakse
AU  - Shashiprabha Punyakantha Dunuweera
Y1  - 2017/06/22
PY  - 2017
N1  - https://doi.org/10.11648/j.ijcocr.20170203.13
DO  - 10.11648/j.ijcocr.20170203.13
T2  - International Journal of Clinical Oncology and Cancer Research
JF  - International Journal of Clinical Oncology and Cancer Research
JO  - International Journal of Clinical Oncology and Cancer Research
SP  - 65
EP  - 74
PB  - Science Publishing Group
SN  - 2578-9511
UR  - https://doi.org/10.11648/j.ijcocr.20170203.13
AB  - Cisplatin is the first anticancer drug based on inorganic complexes which was discovered accidentally by Rosenberg in 1965. Cisplatin is now used to treat a wide range of cancers such as head and neck testicular, small-cell lung and non-small-cell lung, bladder, cervical and ovarian cancers. Cisplatin has become the premier in combination therapy for solid tumours such as gastric, bladder, cervical, ovarian, lung, breast, head and neck cancers and some malignant mesothelioma and some less common cancers. This review begins with an introduction to the accidental discovery of cisplatin highlighting the amazing fact of serendipity involved in drug discovery. This will follow a reviewing of chemistry of cisplatin, identification of cis and trans isomers of diamminedicholoroplatinum(II). As for the most relevance to Pharmacy the action of cisplatin is reviewed next. Highlighted there are the reasons for cisplatin toxicity and hence ways and means of reducing cytotoxicity of cisplatin to healthy cells. Finally, the work on encapsulation of cisplatin in porous calcium carbonate nanoparticles for safe and targeted delivery to cancerous cells for more effective and selective action on cancer cells will be discussed.
VL  - 2
IS  - 3
ER  -

Copy | Download

Author Information

Rajapakse Mudiyanselage Gamini Rajapakse

Department of Chemistry, University of Peradeniya, Peradeniya, Sri Lanka
Shashiprabha Punyakantha Dunuweera

Department of Chemistry, University of Peradeniya, Peradeniya, Sri Lanka

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Rajapakse Mudiyanselage Gamini Rajapakse, Shashiprabha Punyakantha Dunuweera. (2017). Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin. International Journal of Clinical Oncology and Cancer Research, 2(3), 65-74. https://doi.org/10.11648/j.ijcocr.20170203.13

Copy | Download

ACS Style

Rajapakse Mudiyanselage Gamini Rajapakse; Shashiprabha Punyakantha Dunuweera. Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin. Int. J. Clin. Oncol. Cancer Res. 2017, 2(3), 65-74. doi: 10.11648/j.ijcocr.20170203.13

Copy | Download

AMA Style

Rajapakse Mudiyanselage Gamini Rajapakse, Shashiprabha Punyakantha Dunuweera. Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin. Int J Clin Oncol Cancer Res. 2017;2(3):65-74. doi: 10.11648/j.ijcocr.20170203.13

Copy | Download

@article{10.11648/j.ijcocr.20170203.13,
  author = {Rajapakse Mudiyanselage Gamini Rajapakse and Shashiprabha Punyakantha Dunuweera},
  title = {Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {2},
  number = {3},
  pages = {65-74},
  doi = {10.11648/j.ijcocr.20170203.13},
  url = {https://doi.org/10.11648/j.ijcocr.20170203.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20170203.13},
  abstract = {Cisplatin is the first anticancer drug based on inorganic complexes which was discovered accidentally by Rosenberg in 1965. Cisplatin is now used to treat a wide range of cancers such as head and neck testicular, small-cell lung and non-small-cell lung, bladder, cervical and ovarian cancers. Cisplatin has become the premier in combination therapy for solid tumours such as gastric, bladder, cervical, ovarian, lung, breast, head and neck cancers and some malignant mesothelioma and some less common cancers. This review begins with an introduction to the accidental discovery of cisplatin highlighting the amazing fact of serendipity involved in drug discovery. This will follow a reviewing of chemistry of cisplatin, identification of cis and trans isomers of diamminedicholoroplatinum(II). As for the most relevance to Pharmacy the action of cisplatin is reviewed next. Highlighted there are the reasons for cisplatin toxicity and hence ways and means of reducing cytotoxicity of cisplatin to healthy cells. Finally, the work on encapsulation of cisplatin in porous calcium carbonate nanoparticles for safe and targeted delivery to cancerous cells for more effective and selective action on cancer cells will be discussed.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Discovery, Chemistry, Anticancer Action and Targeting of Cisplatin
AU  - Rajapakse Mudiyanselage Gamini Rajapakse
AU  - Shashiprabha Punyakantha Dunuweera
Y1  - 2017/06/22
PY  - 2017
N1  - https://doi.org/10.11648/j.ijcocr.20170203.13
DO  - 10.11648/j.ijcocr.20170203.13
T2  - International Journal of Clinical Oncology and Cancer Research
JF  - International Journal of Clinical Oncology and Cancer Research
JO  - International Journal of Clinical Oncology and Cancer Research
SP  - 65
EP  - 74
PB  - Science Publishing Group
SN  - 2578-9511
UR  - https://doi.org/10.11648/j.ijcocr.20170203.13
AB  - Cisplatin is the first anticancer drug based on inorganic complexes which was discovered accidentally by Rosenberg in 1965. Cisplatin is now used to treat a wide range of cancers such as head and neck testicular, small-cell lung and non-small-cell lung, bladder, cervical and ovarian cancers. Cisplatin has become the premier in combination therapy for solid tumours such as gastric, bladder, cervical, ovarian, lung, breast, head and neck cancers and some malignant mesothelioma and some less common cancers. This review begins with an introduction to the accidental discovery of cisplatin highlighting the amazing fact of serendipity involved in drug discovery. This will follow a reviewing of chemistry of cisplatin, identification of cis and trans isomers of diamminedicholoroplatinum(II). As for the most relevance to Pharmacy the action of cisplatin is reviewed next. Highlighted there are the reasons for cisplatin toxicity and hence ways and means of reducing cytotoxicity of cisplatin to healthy cells. Finally, the work on encapsulation of cisplatin in porous calcium carbonate nanoparticles for safe and targeted delivery to cancerous cells for more effective and selective action on cancer cells will be discussed.
VL  - 2
IS  - 3
ER  -

Copy | Download